Dabigatran

Dabigatran etexilate is a prodrug that is rapidly converted to Dabigatran, a direct, reversible inhibitor of thrombin, used in prevention of stroke and systemic embolism in atrial fibrillation, and treatment/prevention of DVT and pulmonary embolism. Mediocon Inc supplies pharmaceutical-grade Dabigatran meeting IP, BP, EP, and USP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Stroke prevention in non-valvular AF
• Deep vein thrombosis (DVT) treatment
• Pulmonary embolism prevention
• Post-surgical thromboprophylaxis

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings